Recent years have seen significant advancements in UC treatment, offering renewed hope for patients seeking effective and ...

Vedolizumab is a biologic medication approved for both intravenous (IV) and subcutaneous (SC) use, with regulatory approvals varying by region. The SC formulation is authorized for use in the ...

The authors of a review article on the future of ustekinumab biosimilars for treating Crohn disease (CD) discussed key ...